Advertisement
JNJ vs LLY
JNJ vs LLY Stock Comparison: Steady Giant vs Growth Powerhouse
Key Takeaways
- JNJ has surged about 18% YTD and 57% over the past year, outpacing LLY's flat YTD and 20% annual gain, driven by strong execution across pharmaceuticals and MedTech.
- LLY boasts explosive growth from GLP-1 drugs like Mounjaro and Zepbound, with Q4 2025 revenue up 43% to $19.3B and 2026 guidance of $80-83B.
- JNJ offers stability with a lower P/E of 22, 2.1% dividend yield, and diversified portfolio, contrasting LLY's higher P/E of 45 and 0.6% yield.
- Recent catalysts include JNJ's 100% success in OMNY-AF study and talc litigation headwinds, while LLY advances oral GLP-1 orforglipron and acquisitions.
- JNJ's market cap stands at $587B versus LLY's $981B, highlighting LLY's premium valuation amid obesity drug dominance.
Introduction
Johnson & Johnson (JNJ) and Eli Lilly (LLY) represent contrasting profiles in the healthcare sector: JNJ as a diversified defensive stalwart spanning pharmaceuticals, MedTech, and consumer health, and LLY as a high-growth innovator powered by blockbuster GLP-1 therapies for diabetes and obesity. This JNJ vs LLY stock comparison examines their recent performance, business drivers, and market positioning amid evolving healthcare trends like pipeline advancements and regulatory shifts. Traders seeking stability and income may lean toward JNJ, while growth-oriented investors eye LLY's momentum in a booming therapeutic area. Understanding these dynamics aids informed decisions on relative performance and portfolio allocation.
JNJ Overview and Recent Performance
Johnson & Johnson, a global healthcare leader, operates through Innovative Medicine (pharma) and MedTech segments, generating $94.2B in 2025 revenue with 5.3% operational growth despite Stelara patent challenges. Recent market activity has propelled JNJ shares up 18% YTD and 57% over the past year to around $243, with a $587B market cap. Q4 sales hit $24.6B (up 9.1%), adjusted EPS $2.46, and 2026 guidance targets ~$100B sales and $11.53 EPS. Positive sentiment stems from oncology/immunology gains (e.g., Darzalex), 100% OMNY-AF study success, and analyst upgrades like Morgan Stanley on pipeline strength. Headwinds include talc litigation verdicts, yet diversified 28+ $1B products and MedTech momentum support steady upward price behavior.
LLY Overview and Recent Performance
Eli Lilly focuses on innovative therapies, particularly GLP-1s Mounjaro and Zepbound, driving 2025 revenue to $65.2B (up 45%). Shares trade near $1,040 with a $981B market cap, flat YTD but up 20% annually after recent pullback. Q4 revenue soared 43% to $19.3B, non-GAAP EPS $7.54 beating estimates, fueled by Mounjaro ($7.4B, +110%) and Zepbound ($4.3B, +123%). 2026 outlook projects $80-83B sales and $33.50-35 EPS. Sentiment reflects strong volume growth, orforglipron oral GLP-1 inventory buildup ahead of FDA decision, Retevmo data, and acquisitions like Orna Therapeutics. Pricing pressures and high valuation temper gains, but pipeline diversification bolsters positioning in obesity/diabetes markets.
Trending AI Robots
Tickeron’s Trending AI Robots page spotlights top-performing AI trading bots, curated from hundreds of algorithms that trade thousands of tickers across stocks, ETFs, and crypto. These bots, powered by machine learning and Financial Learning Models, feature annualized returns from +15% to over +300%, win rates of 55-95%, and profit factors up to 22.5, adapting to current market conditions like semiconductor booms, aerospace growth, and volatility in biotech/mining. Styles vary: technical dip-buyers on 5-60 minute timeframes, multi-ticker hedging for downtrends, corridor TP/SL strategies (2-10% risk), and sector-focused agents (e.g., biotechnology ETF BIB with 94% win rate). Only the most suitable for volatility and trends earn trending status. Explore these for data-driven ideas at Trending AI Robots.
Head-to-Head Comparison
JNJ's diversified model—pharma (oncology, immunology), MedTech—delivers steady 5-7% growth and resilience versus LLY's concentrated GLP-1 reliance (56% of revenue), enabling 40%+ surges but higher volatility. JNJ's recent momentum (13% monthly gain) outshines LLY's (-4% monthly), with superior YTD/1Y returns amid LLY's post-peak consolidation. Growth drivers contrast: JNJ's 51 approvals/32 filings in 2025 versus LLY's obesity dominance and oral GLP-1 potential. Risks include JNJ's talc suits and tariffs, LLY's supply/pricing pressures. JNJ's lower P/E (22 vs 45), higher yield (2.1% vs 0.6%), and cash buffer favor defensive sentiment; LLY commands growth premium via catalysts like orforglipron.
Tickeron AI Verdict
Tickeron’s AI models currently favor LLY for superior earnings momentum, blockbuster GLP-1 trends, and 2026 growth trajectory, positioning it ahead in bullish innovative pharma environments. JNJ suits stability-focused strategies with consistent execution and dividends, but LLY's relative strength signals higher probabilistic near-term upside absent disruptions.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and LLY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 4 FA rating(s) are green whileLLY’s FA Score has 4 green FA rating(s).
- JNJ’s FA Score: 4 green, 1 red.
- LLY’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 3 bullish TA indicator(s).
- JNJ’s TA Score: 6 bullish, 3 bearish.
- LLY’s TA Score: 3 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +1.51% price change this week, while LLY (@Pharmaceuticals: Major) price change was -1.72% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.81%. For the same industry, the average monthly price growth was +7.81%, and the average quarterly price growth was +4.81%.
Reported Earning Dates
JNJ is expected to report earnings on Jul 15, 2026.
LLY is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.81% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| JNJ | LLY | JNJ / LLY | |
| Capitalization | 567B | 1.01T | 56% |
| EBITDA | 33.7B | 36.2B | 93% |
| Gain YTD | 15.137 | 5.444 | 278% |
| P/E Ratio | 27.31 | 40.12 | 68% |
| Revenue | 96.4B | 72.2B | 134% |
| Total Cash | 22.1B | 5.28B | 418% |
| Total Debt | 55B | 43.4B | 127% |
JNJ | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 12 | 12 | |
SMR RATING 1..100 | 36 | 12 | |
PRICE GROWTH RATING 1..100 | 24 | 19 | |
P/E GROWTH RATING 1..100 | 17 | 88 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (13) in the Pharmaceuticals Major industry is in the same range as LLY (19). This means that JNJ’s stock grew similarly to LLY’s over the last 12 months.
JNJ's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is in the same range as LLY (12). This means that JNJ’s stock grew similarly to LLY’s over the last 12 months.
LLY's SMR Rating (12) in the Pharmaceuticals Major industry is in the same range as JNJ (36). This means that LLY’s stock grew similarly to JNJ’s over the last 12 months.
LLY's Price Growth Rating (19) in the Pharmaceuticals Major industry is in the same range as JNJ (24). This means that LLY’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for LLY (88). This means that JNJ’s stock grew significantly faster than LLY’s over the last 12 months.
| JNJ | LLY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 24% | 1 day ago 69% |
| Stochastic ODDS (%) | 1 day ago 40% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 42% | N/A |
| MACD ODDS (%) | 1 day ago 29% | 1 day ago 73% |
| TrendWeek ODDS (%) | 1 day ago 43% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 46% | 1 day ago 68% |
| Advances ODDS (%) | 7 days ago 44% | 9 days ago 69% |
| Declines ODDS (%) | 15 days ago 42% | 1 day ago 56% |
| BollingerBands ODDS (%) | N/A | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 71% |
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AMGN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AMGN could also see price increases.